Status:
COMPLETED
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
Lead Sponsor:
Astion Pharma A/S
Conditions:
Discoid Lupus Erythematosus
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to ...
Eligibility Criteria
Inclusion
- A clinical diagnosis of either DLE or SLE
- Histological results from biopsy confirming the diagnosis (biopsy can be taken at screening)
- Is prepared to grant authorised persons access to the medical records
- Has signed informed consent
Exclusion
- Has an active skin disease other than DLE or another progressive or serious disease that interferes with the study outcome
- Has scarring at the target lesion
- Systemic treatment of SLE
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00625521
Start Date
November 1 2006
End Date
July 1 2007
Last Update
February 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Filippa Nyberg
Danderyd Stockholm, Sweden